Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Lyle Craker, Ph.D.,
Cannabis Law Report
SEPTEMBER 23, 2019
Due to the Schedule I classification by the Drug Enforcement Agency (DEA), researchers seeking to investigate health effects associated with cannabis must follow a regimented application process. 55 The 2010 law requires states to enact laws for reporting substance use-exposed infants to child protective services. Conclusion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Meadow
JULY 13, 2018
I moved to San Francisco in 2006 and started my time in city government in 2009, so I spent over a decade in city hall working for two administrations. We’ve had a cap on that really since 2010 and one way or another, we’ve codified that now to a number of 30. NICOLE: All right, I’ll start with me. That was a big question.
Cannabis Law Report
JULY 12, 2019
31) The United States DEA has stated that small amounts of other cannabinoids will also occur in all cannabis extracts, even those that purport to be CBD only – unless synthesized de novo, CBD isolate will always contain small amounts of THC when extracted from a plant. British Journal of Nutrition (2010), 104, 803–806. September 2004.
Cannabis Law Report
MARCH 25, 2019
The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 9, 2006 , 120 Stat. 201, July 27, 2006 , 120 Stat. 3, 2010 , 124 Stat. 611 ; Pub.
Expert insights. Personalized for you.
52 
Let's personalize your content